-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Recco Bio-B (02179.HK) announced that the phase III clinical trial of the new adjuvant recombinant herpes zoster vaccine REC610 independently developed by the group has been completed. Registration number: CTR20243742. The company has recently obtained the clinical trial summary report of this study.

Zhitongcaijing·10/29/2026 09:01:16
Listen to the news
Zhitong Finance App News, Recco Bio-B (02179.HK) announced that the phase III clinical trial of the new adjuvant recombinant herpes zoster vaccine REC610 independently developed by the group has been completed. Registration number: CTR20243742. The company has recently obtained the clinical trial summary report of this study.